15:33 , May 25, 2018 |  BC Week In Review  |  Clinical News

Agios reports Phase I safety data for IDH1/IDH2 inhibitor

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) reported safety data from 93 evaluable patients in a Phase I trial evaluating AG-881 to treat advanced solid tumors, including glioma, in patients with an isocitrate dehydrogenase 1 (IDH1) or IDH2...
05:42 , Jan 27, 2018 |  BioCentury  |  Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
00:31 , May 18, 2016 |  BC Extra  |  Top Story

Celgene, Agios form new oncology deal, revise another

Celgene Corp. (NASDAQ:CELG) and Agios Pharmaceuticals Inc. (NASDAQ:AGIO) formed a new research collaboration to explore metabolic immuno-oncology. The companies also amended their 2010 cancer metabolism deal, returning to Agios worldwide rights to mutated isocitrate dehydrogenase...
08:00 , Nov 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Isocitrate dehydrogenase 1 (IDH1)

Cancer INDICATION: Acute myelogenous leukemia (AML) In vitro and mouse studies identified an inhibitor of mutant IDH1 that could help treat AML. Screening of a library of small molecules for binding to a heterodimer of...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

AG-881: Phase I started

Agios began an open-label, dose-escalation, U.S. Phase I trial to evaluate once-daily oral AG-881 in about 150 patients. The companies partnered to develop and commercialize AG-881 worldwide (see BioCentury, May 4). Agios Pharmaceuticals Inc. (NASDAQ:AGIO),...
07:00 , May 4, 2015 |  BC Week In Review  |  Company News

Agios, Celgene deal

The companies partnered to develop and commercialize AG-881 worldwide. Agios said it expects a Phase I trial of the inhibitor of mutated isocitrate dehydrogenase 1 (IDH1) and IDH2 to begin this quarter. The company declined...
07:00 , May 4, 2015 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
01:52 , Apr 30, 2015 |  BC Extra  |  Company News

Celgene strikes cancer deals with Agios, Northern Biologics

Celgene Corp. (NASDAQ:CELG) licensed its third asset from Agios Pharmaceuticals Inc. (NASDAQ:AGIO), acquiring rights to develop and commercialize AG-881, an inhibitor of mutated isocitrate dehydrogenase 1 (IDH1) and isocitrate dehydrogenase 2 ( IDH2 ). Agios...